Table 1 Distribution of patient, tumour, and treatment characteristics of invasive breast cancer according to the mode of detection
From: Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers
SP group (n = 878) | IC group (n = 181) | NSP group (n = 554) | SP vs. IC group | SP vs. NSP group | IC vs. NSP group | ||||
|---|---|---|---|---|---|---|---|---|---|
n | (%) | n | (%) | n | (%) | p | p | p | |
Age | 0.060 | 0.307 | 0.236 | ||||||
> 65 years | 319 | (36.3) | 52 | (28.7) | 186 | (33.6) | |||
≤ 65 years | 559 | (63.7) | 129 | (71.3) | 368 | (66.4) | |||
TNM stage | < 0.001 | < 0.001 | < 0.001 | ||||||
I | 560 | (63.8) | 67 | (37.0) | 227 | (41.0) | |||
II | 255 | (29.0) | 86 | (47.5) | 174 | (31.4) | |||
III | 47 | (5.4) | 21 | (11.6) | 77 | (13.9) | |||
IV | 9 | (1.0) | 7 | (3.9) | 65 | (11.7) | |||
Unknown | 7 | (0.8) | 0 | (0.0) | 11 | (2.0) | |||
Extent of disease | < 0.001 | < 0.001 | 0.0014 | ||||||
Tumor with local spread (any T/N0/M0) | 647 | (73.7) | 105 | (58.0) | 315 | (56.9) | |||
T1 | 560 | (86.6) | 67 | (63.8) | 227 | (72.1) | |||
T2 | 78 | (12.1) | 31 | (29.5) | 71 | (22.5) | |||
T3 | 8 | (1.2) | 5 | (4.8) | 5 | (1.6) | |||
T4 | 1 | (0.1) | 2 | (1.9) | 12 | (3.8) | |||
Tumor with regional spread (any T/N+/M0) | 215 | (24.5) | 69 | (38.1) | 163 | (29.4) | |||
Advanced cancer (any T/any N/M+) | 9 | (1.0) | 7 | (3.9) | 65 | (11.7) | |||
Unknown | 7 | (0.8) | 0 | (0.0) | 11 | (2.0) | |||
SBR grade | 0.001 | 0.022 | 0.147 | ||||||
1 | 228 | (26.0) | 27 | (14.9) | 115 | (20.8) | |||
2 | 486 | (55.4) | 109 | (60.2) | 299 | (54.0) | |||
3 | 136 | (15.5) | 42 | (23.2) | 110 | (19.9) | |||
Unknown or not assessed | 28 | (3.2) | 3 | (1.7) | 30 | (5.4) | |||
Hormonal receptor status | < 0.001 | < 0.001 | 0.171 | ||||||
OR+/PR+ | 633 | (72.1) | 105 | (58.0) | 331 | (59.8) | |||
OR+/PR- or OR-/PR+ | 137 | (15.6) | 32 | (17.7) | 109 | (19.7) | |||
OR-/PR- | 88 | (10.0) | 41 | (22.7) | 89 | (16.1) | |||
Unknown or not assessed | 20 | (2.3) | 3 | (1.7) | 25 | (4.5) | |||
Her-2 receptor status | 0.350 | 0.068 | 0.899 | ||||||
Positive | 86 | (9.8) | 23 | (12.7) | 72 | (13.0) | |||
Negative | 699 | (79.6) | 146 | (80.7) | 427 | (77.1) | |||
Unknown or not assessed | 93 | (10.6) | 12 | (6.6) | 55 | (9.9) | |||
Type of treatment | < 0.001 | < 0.001 | < 0.001 | ||||||
Surgery ± RT | 535 | (60.9) | 60 | (33.2) | 233 | (42.1) | |||
Surgery + CT ± RT | 293 | (33.4) | 91 | (50.3) | 199 | (35.9) | |||
Neoadjuvant treatment a+ Surgery ± CT/RT | 43 | (4.9) | 27 | (14.9) | 68 | (12.3) | |||
No surgery (refusal, palliative treatment) | 3 | (0.3) | 3 | (1.7) | 45 | (8.1) | |||
Unknown | 4 | (0.5) | – | – | 9 | (1.6) | |||
Type of surgery | 0.045 | < 0.001 | 0.113 | ||||||
Breast-conserving surgery | 692 | (78.8) | 129 | (71.3) | 327 | (59.0) | |||
Mastectomy | 178 | (20.3) | 49 | (27.1) | 171 | (30.9) | |||
Unknown or no surgery | 8 | (0.9) | 3 | (1.7) | 56 | (10.1) | |||